This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DNA's Rituxan Flunks MS Trial

Updated from 7:06 a.m. EDT

Rituxan is an ineffective treatment for primary progressive multiple sclerosis, according to results of a phase III clinical trial released Monday night by the drug's makers Genentech (DNA) and Biogen Idec (BIIB - Get Report).

The failed study is a setback to the companies' efforts to expand Rituxan use into new autoimmune diseases, although it was widely acknowledged that Rituxan faced long odds because primary progressive multiple sclerosis (PPMS) is an intractable disease in which many drugs have failed to show efficacy, including drugs used very successfully to treat other forms of multiple sclerosis.

The study enrolled 439 patients with PPMS and randomized them to receive four intravenous courses of Rituxan six months apart or a placebo. At the end of 96 weeks, however, Rituxan failed to slow the course of the disease compared to placebo, the companies said.

Genentech and Biogen Idec reported 2007 Rituxan sales of $2.29 billion in the United States, primarily as a treatment for the blood cancer non-Hodgkin's lymphoma. The drug is also approved to treat rheumatoid arthritis.

The failure of Rituxan in the PPMS trial shouldn't impact earnings of either company since the high-risk nature of the trial dissuaded most analysts from including revenue in their financial models.

A positive result could have added between $250 million and $400 million annually to the Rituxan franchise, according to various analyst estimates.

In multiple sclerosis, the body's own immune system is thought to attack myelin, a fatty, protective sheath that surrounds nerve fibers in the brain and spinal cord. A breakdown in myelin, therefore, damages underlying neurons and interferes with electrical signals that the brain sends through the spinal cord to the rest of the body.

PPMS accounts for about 10% of the estimated 400,000 people with multiple sclerosis in the United States. It is considered a more severe form of the disease because patients tend to lose motor function, experience muscle tremors and numbness steadily over time.

By contrast, patients with relapsing, remitting multiple sclerosis, or RRMS, the most common form of the disease, experience the same degenerative symptoms, but the disease can wax and wane, with patients suffering periods of exacerbation followed by recovery.

Drugs like Biogen Idec's Avonex and Tysabri and Teva's (TEVA - Get Report) Copaxone are effective in treating RRMS, but not PPMS for reasons scientists don't fully understand.

A phase II study presented last year showed Rituxan to be effective in treating RRMS. This study offered some reason for optimism that Monday's PPMS trial would also be successful.

Genentech and Biogen Idec are studying Rituxan in patients with lupus, another hard-to-treat autoimmune disease, with results expected within the next few weeks.

Prior to the Rituxan announcement, Genentech shares closed Monday down $2.10 to $74.69. Biogen Idec shares were off 50 cents to $63.72.

Know What You Own: DNA operates in the biotechnology and healthcare sector, and some of the other stocks in its field include Amgen (AMGN - Get Report), Bristol-Myers Squibb (BMY - Get Report) and Glaxosmithkline (GSK - Get Report). These stocks were recently trading at $43.02, +0.16%, $21.59, +0.19% and $42.49, +0.35% respectively. For more on the value of knowing what you own, visit TheStreet.com's Investing A-to-Z section.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMGN $153.26 -1.12%
BIIB $404.28 -0.28%
BMY $67.48 -0.28%
GSK $42.26 0.28%
TEVA $61.56 1.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs